A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

http://www.wikidata.org/entity/Q34724614

about

Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasis What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors.QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review Experience with sorafenib in the treatment of advanced renal cell carcinoma.Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors.A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.Treatment selection in metastatic renal cell carcinoma: expert consensus.Treating patients with metastatic renal carcinoma: an escape from Phase III.Interactions between oral antineoplastic agents and concomitant medication: a systematic review.Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor.Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity.Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.Results of a phase I, open-label, randomized, crossover study evaluating the effects of linifanib on QTc intervals in patients with solid tumors Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis.Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers.Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity

P2860

Q22305863-65C50EA5-1245-4540-AD99-FC672A68BD45 Q26782585-D34D587E-6766-44C1-91D2-E11386CCB71B Q35198387-B42889AF-3E01-439E-8ABD-7ADD893F1680 Q35677270-B90E9CD3-6478-479D-9EC9-CB8D27C73E0A Q35914782-E8811489-328F-4171-80D4-964CF9EC4087 Q36136849-F3150C57-3D72-480A-9732-3CB77902529B Q36270115-F7F13F85-BB80-4D73-9C64-DE8CCBE0A369 Q36379345-1620CC9A-B816-4362-8DE8-94A9B9DA3867 Q36594084-3470F97D-A70F-41F1-9921-5DBE777E6A97 Q37283736-3DB92E7C-A285-424F-9015-A67DEBC9CE57 Q37507871-6C0A108B-980A-48EE-84ED-CCF4712C310D Q37537655-1813B20C-8856-42C1-8032-50DB672785CE Q37999655-AA6E8950-A443-4A39-9BD0-C7EB06FD4DA1 Q38030592-820B4E88-3F28-4B7F-94FD-C432B198A06C Q38099040-57ABF508-E981-4C11-BB30-52C6E7C2822B Q38110320-F3B3646E-B820-40FA-B84A-1DCE9BABCD56 Q38155199-BADD37AC-29F8-4BF1-A6EE-A5DAB52D0D0C Q38190857-B5DC1C6C-B52A-45A5-917C-7EFBDC37FD74 Q40770030-DE25465D-ED82-4589-88D0-4D956699A04E Q41816476-56BA24F6-244A-4FE0-BD1D-3ACD3CECAEF1 Q42136590-E9AF6A81-377D-4CDD-B208-5B4804A577AE Q42703704-F0B74145-EC13-457E-BB37-A89F0345CAC7 Q43657215-82D25CBC-2BCE-4CEC-A423-A162A451697E Q44591315-3AB9E095-01E6-4599-852D-12035AC76A1A Q47727992-60F679E4-049E-401B-B0C9-062F4F205B67 Q47969048-53CB37F7-1644-48B2-B54A-7E534D1589E6 Q49244147-4BB3982F-7ED1-41A4-B06F-A7610FF2F92A Q52863110-FC99B06E-41C8-4E20-B1E8-AAE0312879D4 Q54196218-09B5C89B-A2C4-4EBF-90FB-D9816DB11F3A Q54365531-E02C85A3-C219-48FA-977C-42BCCEB3E6D8 Q58548679-AFFC00B7-A00C-4019-AF94-7B5E941274FD

P2860

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

http://www.wikidata.org/entity/Q34724614

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

A phase I open-label study eva ...... patients with advanced cancer.

@ast

A phase I open-label study eva ...... patients with advanced cancer.

@en

A phase I open-label study eva ...... patients with advanced cancer.

@nl

type

label

A phase I open-label study eva ...... patients with advanced cancer.

@ast

A phase I open-label study eva ...... patients with advanced cancer.

@en

A phase I open-label study eva ...... patients with advanced cancer.

@nl

prefLabel

A phase I open-label study eva ...... patients with advanced cancer.

@ast

A phase I open-label study eva ...... patients with advanced cancer.

@en

A phase I open-label study eva ...... patients with advanced cancer.

@nl

P1433

Q34724614-09A013DE-66FF-415C-8EC5-E63ECDB4F8CB

P1476

Q34724614-A66B4328-DF70-49A7-BF67-34B46B512ACD

P2093

Q34724614-1357B0BE-CE56-4D41-ABB5-5E50A072ADAD

Q34724614-2D00BA8A-A2ED-4566-AC5B-F2A921C96F9D

Q34724614-40E4F848-6F57-4A72-8F34-3EED87093EEA

Q34724614-8A3B2FC9-F1C6-49A7-AD5A-5C6E4D2827C4

Q34724614-BE19DAC3-C6E9-4300-8CFA-616302503AF0

Q34724614-E0A37E3D-2123-4F27-A444-DF8FB4DC0647

Q34724614-E24F4C8D-4ED1-479E-8C9D-2D0A32D56467

P2860

Q34724614-05F45C38-741F-401A-9BA0-224637C6FE35

Q34724614-202212C4-77EC-4161-9F2B-157E145C0097

Q34724614-2475E93A-7F99-4850-BCBF-B2512BB9E418

Q34724614-2DD70604-7F35-412E-A6AF-340EA30E49ED

Q34724614-335F04A2-BA07-4639-B8FB-7D1EB5D8D755

Q34724614-37AEE0F2-76EE-4E5B-80E2-B2A597976369

Q34724614-391973CC-F25A-4A5B-8ED8-4EF6F4525DD7

Q34724614-3E2D12E5-0988-4FB2-A9D0-2D26E1098EDC

Q34724614-4178F76A-EDF3-4526-9A3B-78F2C3CE9A09

Q34724614-44E3929E-A705-4680-8D51-9D5BF9F2542F

P2888

Q34724614-2572F5D7-B37C-4457-A473-6F4519489B07

P304

Q34724614-0D602CDF-E681-46E4-B442-AA76A0943716

P31

Q34724614-21ED42FD-19B4-44C9-9AFD-A5ACF27EAD47

P356

Q34724614-95685BBF-13DB-4E66-A627-9633BF7187C2

P433

Q34724614-21B838AA-EEA5-44AB-B9A1-9B6707722E23

P478

Q34724614-7DD1876C-0978-410E-ADF5-3675518F61CE

P577

Q34724614-E805DB7F-8F88-4903-9179-E69D225AE061

P5875

Q34724614-B8A18617-13F4-4157-8513-41CA410E7FD4

P6179

Q34724614-B1B4CE73-8683-4826-A920-C08CC8557524

P698

Q34724614-9855F5E8-89E2-4791-8A79-826CA40406A8

P921

Q34724614-85575CB5-D3D1-496D-8A1F-F1F1E1A2FBAA

Q34724614-FFCAA95E-31E1-4AB6-A04B-4C32F340495A

P932

Q34724614-4DF80582-62B9-404E-98A6-338C1F5DFF16

P356

S00280-010-1372-3

P1433

Cancer Chemotherapy and Pharmacology

P1476

A phase I open-label study eva ...... patients with advanced cancer.

@en

P2093

Alain C Mita

http://www.w3.org/2001/XMLSchema#string

Anthony W Tolcher

http://www.w3.org/2001/XMLSchema#string

Arthur Mazzu

http://www.w3.org/2001/XMLSchema#string

Frank Cihon

http://www.w3.org/2001/XMLSchema#string

Geoffrey I Shapiro

http://www.w3.org/2001/XMLSchema#string

Leonard J Appleman

http://www.w3.org/2001/XMLSchema#string

Pavur R Sundaresan

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced hepatocellular carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

Interpreting disparate responses to cancer therapy: the role of human population genetics.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

P2888

s00280-010-1372-3

P304

751-764

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-010-1372-3

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

67

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44647158

http://www.w3.org/2001/XMLSchema#string

P6179

1032910148

http://www.w3.org/2001/XMLSchema#string

P698

20521052

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3064895

http://www.w3.org/2001/XMLSchema#string